- Home
- STRO vs ZURA Comparison
STRO vs ZURA Comparison
Compare STRO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | ZURA |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 252.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | STRO | ZURA |
|---|---|---|
| Price | $11.12 | $4.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $18.29 | $11.38 |
| AVG Volume (30 Days) | 105.4K | ★ 639.4K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,646,000.00 | N/A |
| Revenue This Year | $63.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $0.97 |
| 52 Week High | $21.50 | $5.75 |
Technical Indicators
Market Signals| Indicator | STRO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 73.40 | 58.49 |
| Support Level | $10.15 | $5.07 |
| Resistance Level | $12.18 | $5.75 |
| Average True Range (ATR) | 0.88 | 0.43 |
| MACD | -0.20 | 0.05 |
| Stochastic Oscillator | 77.27 | 50.54 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.